Wells Fargo analyst Derek Archila maintains $Septerna (SEPN.US)$ with a buy rating, and maintains the target price at $43.
According to TipRanks data, the analyst has a success rate of 46.3% and a total average return of 10.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Septerna (SEPN.US)$'s main analysts recently are as follows:
Septerna is noted for its unique position within the broader biopharma landscape, by deploying predictive high-throughput screening along with SAR optimization focussed on G protein-coupled receptor targets. The company's strategic execution of a highly attractive pipeline, targeting validated entities in substantial, established indications where an oral option presents a clear advantage to patients, is particularly noteworthy.
There is potential upside for the shares based on the Phase 1 results of SEP-786, considered to be promising due to existing data from similar parathyroid hormone programs. Septerna's SEP-631 is regarded as a significant but unrecognized asset. The company's Native Complex platform approach and the preclinical data of SEP-786 are expected to effectively transition into clinical stages.
The company is leveraging its Native Complex platform to develop a pipeline of oral small molecule G protein-coupled receptor drugs. There is seen as significant potential for stock appreciation rooted in validated targets within sizable markets.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富国集团分析师Derek Archila维持$Septerna (SEPN.US)$买入评级，维持目标价43美元。
根据TipRanks数据显示，该分析师近一年总胜率为46.3%，总平均回报率为10.0%。
此外，综合报道，$Septerna (SEPN.US)$近期主要分析师观点如下：
Septerna在更广泛的生物制药领域中以其独特的地位而引人注目，通过实施预测性高通量筛选以及专注于G蛋白偶联受体靶点的SAR优化。该公司在战略上执行一个极具吸引力的产品管线，针对经过验证的实体，特别是在那些口服选择对患者具有明显优势的成熟适应症中的表现尤为突出。
根据SEP-786的第一阶段结果，股票存在潜在的上行空间，由于与类似的副甲状腺激素项目的现有数据相比，这些结果被认为是有前景的。Septerna的SEP-631被认为是一个重要但未被认可的资产。该公司的Native Complex平台方法以及SEP-786的临床前数据预计将有效过渡到临床阶段。
该公司正在利用其Native Complex平台开发一系列口服小分子G蛋白偶联受体药物。预计在大型市场中，基于经过验证的靶点，股票增值的潜力是显著的。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
